Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
Psychedelics biopharma company Lobe Sciences Ltd. (OTCQB: LOBEF ) signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 million for an annual term with a 15% interest. Funding for psychedelics research and clinical trials is certainly here to stay. In the last couple of weeks, other biotech companies advancing both classic and next-generation psychedelic medicines such as Bright Minds (NASDAQ: DRUG ), ATAI Life Sciences (NASDAQ: ATAI ) and Freedom Biosciences have also signed considerable loan agreements with major … Full story available on Benzinga.com
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
Psychedelics biopharma company Lobe Sciences Ltd. (OTCQB: LOBEF ) signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 million for an annual term with a 15% interest. Funding for psychedelics research and clinical trials is certainly here to stay. In the last couple of weeks, other biotech companies advancing both classic and next-generation psychedelic medicines such as Bright Minds (NASDAQ: DRUG ), ATAI Life Sciences (NASDAQ: ATAI ) and Freedom Biosciences have also signed considerable loan agreements with major … Full story available on Benzinga.com